Brought to you by 
Alizyme brings in £11.5mm
21 Nov 2003
Executive Summary
Alizyme PLC (developing drugs for obesity and gastrointestinal disorders) grossed £11.5mm ($19.2mm) with the private placement of about 6.84mm new ordinary shares priced at £1.68 each (a 3% discount based on the market the day prior to the announcement) to institutional investors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alizyme brings in £11.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice